AIM ImmunoTech reports positive Phase III data of Ampligen for long Covid
AIM ImmunoTech has reported positive initial pilot study data from its Phase III trial of an investigational drug, Ampligen, for long Covid.
Source: clinicaltrialsarena.com
Page 28 - Expanded Access Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Expanded Access Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Expanded Access Program Today - Breaking & Trending Today
NA Proactive news snapshot: VolitionRx Limited, AIM ImmunoTech Inc, Montero Mining and Exploration Ltd, Healixa Inc, Ortho Regenerative Technologies Inc, Gold Resource Corporation UPDATE ...
VolitionRx Limited announced that it has commenced an underwritten public offering of common stock. The size and scope of the offering will depend on market...
Source: proactiveinvestors.com
FDA Provides Update on Agency Response to Monkeypox Outbreak
/PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an update on its multipronged response to monkeypox in the United States, including...
Source: prnewswire.com
FDA Provides Update on Agency Response to Monkeypox Outbreak
/PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an update on its multipronged response to monkeypox in the United States, including...
Source: prnewswire.com
AIM ImmunoTech Inc reveals positive pilot study data from EAP evaluating Ampligen for treatment of Long COVID
AIM ImmunoTech Inc (NYSE:AIM) has announced what it calls positive preliminary pilot study data from its ongoing Expanded Access Program (EAP) evaluating...
Source: proactiveinvestors.com